A citation-based method for searching scientific literature

Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri, Neil Chanchlani, Neel M Heerasing, Peter Hendy, Simeng Lin, Daniel R Gaya, J R Fraser Cummings, Christian P Selinger, Charlie W Lees, Ailsa L Hart, Miles Parkes, Shaji Sebastian, John C Mansfield, Peter M Irving, James Lindsay, Richard K Russell, Timothy J McDonald, Dermot McGovern, James R Goodhand, Tariq Ahmad. Lancet Gastroenterol Hepatol 2019
Times Cited: 225







List of co-cited articles
828 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Infliximab, azathioprine, or combination therapy for Crohn's disease.
Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard,[...]. N Engl J Med 2010
32

HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Aleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, Graham A Heap, Daniel L Rice, Mark Reppell, Claire M Bewshea, Neil Chanchlani, Gareth J Walker, Mandy H Perry,[...]. Gastroenterology 2020
115
27

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Niels Vande Casteele, Marc Ferrante, Gert Van Assche, Vera Ballet, Griet Compernolle, Kristel Van Steen, Steven Simoens, Paul Rutgeerts, Ann Gils, Séverine Vermeire. Gastroenterology 2015
555
23

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
Joseph D Feuerstein, Geoffrey C Nguyen, Sonia S Kupfer, Yngve Falck-Ytter, Siddharth Singh. Gastroenterology 2017
288
22

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao,[...]. Lancet 2002
22

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Amit Assa, Manar Matar, Dan Turner, Efrat Broide, Batia Weiss, Oren Ledder, Anat Guz-Mark, Firas Rinawi, Shlomi Cohen, Chani Topf-Olivestone,[...]. Gastroenterology 2019
89
23

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Konstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, Peter M Irving, Niels Vande Casteele, Patricia L Kozuch, Laura E Raffals, Leonard Baidoo, Brian Bressler, Shane M Devlin,[...]. Clin Gastroenterol Hepatol 2019
116
16

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
795
16

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Remo Panaccione, Subrata Ghosh, Stephen Middleton, Juan R Márquez, Boyd B Scott, Laurence Flint, Hubert J F van Hoogstraten, Annie C Chen, Hanzhe Zheng, Silvio Danese,[...]. Gastroenterology 2014
554
16

Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Xavier Roblin, Nicolas Williet, Gilles Boschetti, Jean-Marc Phelip, Emilie Del Tedesco, Anne-Emmanuelle Berger, Philippe Vedrines, Gerard Duru, Laurent Peyrin-Biroulet, Stéphane Nancey,[...]. Gut 2020
48
33

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Geert D'Haens, Severine Vermeire, Guy Lambrecht, Filip Baert, Peter Bossuyt, Benjamin Pariente, Anthony Buisson, Yoram Bouhnik, Jérôme Filippi, Janneke Vander Woude,[...]. Gastroenterology 2018
154
15

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D Kent,[...]. Gastroenterology 2007
15

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Magali Lemaitre, Julien Kirchgesner, Annie Rudnichi, Fabrice Carrat, Mahmoud Zureik, Franck Carbonnel, Rosemary Dray-Spira. JAMA 2017
255
14

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Joana Torres, Stefanos Bonovas, Glen Doherty, Torsten Kucharzik, Javier P Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager,[...]. J Crohns Colitis 2020
280
14

Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler,[...]. N Engl J Med 2013
14

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L Peyrin-Biroulet, W Sandborn, B E Sands, W Reinisch, W Bemelman, R V Bryant, G D'Haens, I Dotan, M Dubinsky, B Feagan,[...]. Am J Gastroenterol 2015
981
14

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Jean-Frédéric Colombel, Omoniyi J Adedokun, Christopher Gasink, Long-Long Gao, Freddy J Cornillie, Geert R D'Haens, Paul J Rutgeerts, Walter Reinisch, William J Sandborn, Stephen B Hanauer. Clin Gastroenterol Hepatol 2019
67
19

Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts, William J Sandborn, Brian G Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B Hanauer, Gary R Lichtenstein,[...]. N Engl J Med 2005
13

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Stephen B Hanauer, William J Sandborn, Paul Rutgeerts, Richard N Fedorak, Milan Lukas, Donald MacIntosh, Remo Panaccione, Douglas Wolf, Paul Pollack. Gastroenterology 2006
13

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Bella Ungar, Idan Levy, Yarden Yavne, Miri Yavzori, Orit Picard, Ella Fudim, Ronen Loebstein, Yehuda Chowers, Rami Eliakim, Uri Kopylov,[...]. Clin Gastroenterol Hepatol 2016
234
13

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Konstantinos Papamichael, Karen A Chachu, Ravy K Vajravelu, Byron P Vaughn, Josephine Ni, Mark T Osterman, Adam S Cheifetz. Clin Gastroenterol Hepatol 2017
133
12

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukas, Filip Baert, Tomas Vaňásek, Ahmet Danalioglu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hébuterne,[...]. Lancet 2017
398
12


British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu'Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger,[...]. Gut 2019
492
12

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
A J Yarur, V Kanagala, D J Stein, F Czul, M A Quintero, D Agrawal, A Patel, K Best, C Fox, K Idstein,[...]. Aliment Pharmacol Ther 2017
153
11

Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.
Sara Lega, Becky L Phan, Casey J Rosenthal, Julia Gordon, Nichola Haddad, Nanci Pittman, Keith J Benkov, Marla C Dubinsky. Inflamm Bowel Dis 2019
47
23

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.
Freddy Cornillie, Stephen B Hanauer, Robert H Diamond, Jianping Wang, Kezhen L Tang, Zhenhua Xu, Paul Rutgeerts, Séverine Vermeire. Gut 2014
264
11

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
W J Sandborn, S B Hanauer, P Rutgeerts, R N Fedorak, M Lukas, D G MacIntosh, R Panaccione, D Wolf, J D Kent, B Bittle,[...]. Gut 2007
727
11

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Julien Kirchgesner, Magali Lemaitre, Fabrice Carrat, Mahmoud Zureik, Franck Carbonnel, Rosemary Dray-Spira. Gastroenterology 2018
237
11

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
11

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
Erwin Dreesen, Filip Baert, David Laharie, Peter Bossuyt, Yoram Bouhnik, Anthony Buisson, Guy Lambrecht, Edouard Louis, Bas Oldenburg, Benjamin Pariente,[...]. Clin Gastroenterol Hepatol 2020
46
23

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Omoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M Davis, Stephen B Hanauer, Brian G Feagan,[...]. Gastroenterology 2018
110
10

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
Shomron Ben-Horin, Matti Waterman, Uri Kopylov, Miri Yavzori, Orit Picard, Ella Fudim, Halim Awadie, Batia Weiss, Yehuda Chowers. Clin Gastroenterol Hepatol 2013
231
10


Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Konstantinos Papamichael, Anna Juncadella, Danny Wong, Shana Rakowsky, Lindsey A Sattler, James P Campbell, Byron P Vaughn, Adam S Cheifetz. J Crohns Colitis 2019
64
15

Crohn's disease.
Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet. Lancet 2017
744
10

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Bent Ascanius Jacobsen, Anne Sophie Oxholm,[...]. Gut 2014
327
10

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
Johannan F Brandse, Gijs R van den Brink, Manon E Wildenberg, Desiree van der Kleij, Theo Rispens, Jeroen M Jansen, Ron A Mathôt, Cyriel Y Ponsioen, Mark Löwenberg, Geert R A M D'Haens. Gastroenterology 2015
254
10

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Omoniyi J Adedokun, William J Sandborn, Brian G Feagan, Paul Rutgeerts, Zhenhua Xu, Colleen W Marano, Jewel Johanns, Honghui Zhou, Hugh M Davis, Freddy Cornillie,[...]. Gastroenterology 2014
229
9

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Jeffrey Hyams, Wallace Crandall, Subra Kugathasan, Anne Griffiths, Allan Olson, Jewel Johanns, Grace Liu, Suzanne Travers, Robert Heuschkel, James Markowitz,[...]. Gastroenterology 2007
573
9

Infliximab maintenance therapy for fistulizing Crohn's disease.
Bruce E Sands, Frank H Anderson, Charles N Bernstein, William Y Chey, Brian G Feagan, Richard N Fedorak, Michael A Kamm, Joshua R Korzenik, Bret A Lashner, Jane E Onken,[...]. N Engl J Med 2004
9

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
William J Sandborn, Christopher Gasink, Long-Long Gao, Marion A Blank, Jewel Johanns, Cynthia Guzzo, Bruce E Sands, Stephen B Hanauer, Stephan Targan, Paul Rutgeerts,[...]. N Engl J Med 2012
727
9

Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
N Mitrev, N Vande Casteele, C H Seow, J M Andrews, S J Connor, G T Moore, M Barclay, J Begun, R Bryant, W Chan,[...]. Aliment Pharmacol Ther 2017
155
9


The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.
Bella Ungar, Yehuda Chowers, Miri Yavzori, Orit Picard, Ella Fudim, Ofir Har-Noy, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin. Gut 2014
212
9

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
David J Gibson, Mark G Ward, Clarissa Rentsch, Antony B Friedman, Kirstin M Taylor, Miles P Sparrow, Peter R Gibson. Aliment Pharmacol Ther 2020
25
36

Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Henit Yanai, Lev Lichtenstein, Amit Assa, Yoav Mazor, Batia Weiss, Arie Levine, Yulia Ron, Uri Kopylov, Yoram Bujanover, Yoram Rosenbach,[...]. Clin Gastroenterol Hepatol 2015
213
9

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Filip Baert, Maja Noman, Severine Vermeire, Gert Van Assche, Geert D' Haens, An Carbonez, Paul Rutgeerts. N Engl J Med 2003
9

Immunogenicity of biologics in inflammatory bowel disease.
Séverine Vermeire, Ann Gils, Paola Accossato, Sadiq Lula, Amy Marren. Therap Adv Gastroenterol 2018
109
9

Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Xavier Roblin, Hubert Marotte, Melanie Rinaudo, Emilie Del Tedesco, Amelie Moreau, Jean Marc Phelip, Christian Genin, Laurent Peyrin-Biroulet, Stephane Paul. Clin Gastroenterol Hepatol 2014
210
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.